ARS Pharmaceuticals, Inc. Cash and Restricted Cash
ARS Pharmaceuticals, Inc. (SPRY) had Cash and Restricted Cash of $8.16 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-13
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $8.16M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $24.32M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $41.32M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $59.56M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents as first filed |
|---|---|---|
| 2026-06-30 | $8.16M 10-Q · filed 2026-08-13 | |
| 2026-03-31 | $24.32M 10-Q · filed 2026-05-15 | |
| 2025-12-31 | $41.32M 10-Q · filed 2026-08-13 | |
| 2025-09-30 | $59.56M 10-Q · filed 2025-11-10 | |
| 2025-06-30 | $51.54M 10-Q · filed 2026-08-13 | |
| 2025-03-31 | $39.86M 10-Q · filed 2026-05-15 | |
| 2024-12-31 | $50.82M 10-Q · filed 2026-08-13 | |
| 2024-09-30 | $39.66M 10-Q · filed 2025-11-10 | |
| 2024-06-30 | $36.63M 10-Q · filed 2025-08-13 | |
| 2024-03-31 | $56.01M 10-Q · filed 2025-05-14 | |
| 2023-12-31 | $70.97M 10-K · filed 2026-03-09 | |
| 2023-09-30 | $60.53M 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $119.02M 10-Q · filed 2024-08-06 | |
| 2023-03-31 | $87.86M 10-Q · filed 2024-05-09 | |
| 2022-12-31 | $210.52M 10-K · filed 2025-03-20 | |
| 2022-09-30 | $37.32M 10-Q · filed 2023-11-09 | $203.47M 10-Q · filed 2022-11-02 |
| 2022-06-30 | $44.59M 10-Q · filed 2023-08-10 | $218.94M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $52.21M 10-Q · filed 2023-05-15 | $234.24M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $60.06M 10-K · filed 2024-03-21 | $254.29M 10-K · filed 2022-03-31 |
| 2021-09-30 | $301.01M 10-Q · filed 2022-11-02 | |
| 2021-06-30 | $360.04M 10-Q · filed 2022-08-11 | |
| 2021-03-31 | $374.56M 10-Q · filed 2022-05-12 | |
| 2020-12-31 | $24.52M 10-K · filed 2023-03-23 | $386.92M 10-Q · filed 2021-05-13 |
| 2020-09-30 | $142.87M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $30.66M 10-Q · filed 2021-08-12 | |
| 2020-03-31 | $24.18M 10-Q · filed 2021-05-13 | |
| 2019-12-31 | $10.53M 10-K · filed 2022-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |